PHASE II TRIAL OF THE PHOSPHATIDYINOSITOL-3 KINASE (PI3K) INHIBITOR BUPARLISIB (BKM120) IN RECURRENT GLIOBLASTOMA CONDUCTED BY THE IVY FOUNDATION EARLY PHASE CLINICAL TRIALS CONSORTIUM

BACKGROUND: The PI3K pathway is activated in most GBMs and represents a potential therapeutic target. Buparlisib is an oral, pan-Class I PI3K inhibitor that enters the brain at therapeutic concentrations and inhibits the growth of U87 and human glioma tumor sphere models. METHODS: The Ivy Consortium...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Wen, Patrick Y., Yung, W. K. Alfred, Mellinghoff, Ingo K., Ramkissoon, Shakti, Alexander, Brian, Rinne, Mikael, Colman, Howard, Omuro, Antonio M., DeAngelis, Lisa M., Gilbert, Mark R., DeGroot, John, Cloughesy, Timothy F., Lee, Eudocia Q., Nayak, Lakshmi, Chi, Andrew S., Batchelor, Tracy, Chang, Susan M., Prados, Michael D., Reardon, David A., Ligon, Keith L.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2014
Assuntos:
abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4144634/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou209.20
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados